Navigation Links
An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
Date:3/10/2010

WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that an acute migraine therapy that is not contraindicated in patients with a history, symptoms or signs of vascular disease and also offers improved efficacy and fast-acting oral delivery would earn a 45 percent patient share in the treatment of migraine, according to surveyed U.S. neurologists. In Europe, such an agent would earn a 30 percent patient share, according to surveyed European neurologists.

The new report entitled Migraine (Acute): Neurologists' Expectations for a New Acute Therapy Extend Beyond Cardiovascular Safety finds that a new acute migraine drug that is free of the triptans' risk of cardiovascular side effects would be valued by clinicians and would enjoy a unique competitive advantage. However, the report shows that such an advantage would not be sufficient to fulfill surveyed neurologists' expectations for a new acute treatment.  

The report also finds Zogenix/Astellas Pharma/Desitin Pharmaceuticals' Sumavel DosePro (needle-free subcutaneous injectable sumatriptan) will earn Decision Resources' proprietary gold-standard status for migraine in 2013. Sumavel DosePro was launched in the U.S. in January 2010 and has been filed for approval in Europe. In 2009, Decision Resources' gold standard for migraine was Merck's Maxalt (rizatriptan oral tablet), owing in part to modest advantages in efficacy over other oral triptans. According to the report, Sumavel DosePro has competitive advantages in efficacy as compared to Maxalt on several of the end points that are most important to surveyed neurologists.  

"Among the current and emerging therapies profiled in the report, Sumavel DosePro benefits from fast-acting and robust efficacy at early time points," said Decision Resources Analyst Jon Searles. "Despite disadvantages in sustained pain freedom and certain side effects, Sumavel DosePro will become our clinical gold standard for migraine in 2013, although we forecast its use will be limited owing to its high cost, generics competition, reimbursement challenges and patient preference for oral pills."

About the Report

Migraine (Acute): Neurologists' Expectations for a New Acute Therapy Extend Beyond Cardiovascular Safety is a DecisionBase 2010 report. DecisionBase 2010 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development. 

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or

registered trademarks of their respective holders.

For more information, contact:

Decision Resources

Christopher Comfort

781-296-2597

ccomfort@dresources.com

SOURCE Decision Resources

Back to top

RELATED LINKS
http://www.decisionresources.com

'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
2. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
5. Biopure Seeks Compassionate Use Protocol for Treatment of Acute Anemia
6. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
7. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
8. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
9. INVEGA(TM) Significantly Reduced Symptoms of Schizophrenia Compared to SEROQUEL(R) in Acutely Ill, Hospitalized Patients
10. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
11. Tezampanel Meets Primary Endpoint in Phase IIb Clinical Trial in Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... -- Endo International plc (NASDAQ: ENDP ) ... , President, U.S. Branded Pharmaceuticals, has decided to ... of a successor. Mr. Lortie joined Endo in ... responsibility for all strategic, commercial and operational functions, ... commercial operations, managed markets, manufacturing, supply chain and ...
(Date:5/5/2016)... Cayman , May 5, 2016 Progra ... trial of Oxitec , s mosquito ... Aedes aegypti by 96 %   ... announced a new plan to fight wild Aedes aegypti, the dangerous ... diseases on the island of Grand Cayman .  MRCU, a ...
(Date:5/5/2016)... 5, 2016 Research and Markets has announced ... Top 5 EU Markets"  report to their offering.  ,     (Logo: ... information on the current Positron Emission Tomography (PET) scanner and ... EU), which includes France , ... Spain and the United Kingdom ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... 06, 2016 , ... This Mother’s Day kicks off the start of an ... National Women’s Health Week takes place May 8-May 14. , Throughout the celebration, ... empower women to make their health a top priority. Women everywhere are being encouraged ...
(Date:5/6/2016)... ... May 06, 2016 , ... RowdMap, ... Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for Medicare and ... Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service Corporation (Blue ...
(Date:5/5/2016)... ... 05, 2016 , ... Pivot Point Consulting achieved ... KLAS Performance Report, Epic Consulting 2016 - Which Firms Provide Breadth, ... consulting services for electronic health record (EHR) solutions from Epic Systems Corporation ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... “deeming regulations” for electronic cigarettes, requiring e-cigarette manufacturers to submit their products ... “tobacco product,” apply to all vaping products that entered the market since February ...
(Date:5/5/2016)... , ... May 05, 2016 , ... TLC Laser Eye ... Diego, California. The laser eye center will now be called “Gordon Schanzlin New Vision ... staff will remain at the full-service facility to ensure that patients continue to receive ...
Breaking Medicine News(10 mins):